{"title":"Adverse Effects of Prolonged Use of Local Disinfectants in the Management of Surgical Wounds: Clinical Observations and Literature Review.","authors":"Benjamin Bajer, Mohamed Boumaiza","doi":"10.4103/idoj.idoj_1506_25","DOIUrl":"https://doi.org/10.4103/idoj.idoj_1506_25","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Tufted Angioma of the Scalp Presenting as a Solitary Papule.","authors":"R Neelima, Akshay S Peethambaran, Satyaki Ganguly","doi":"10.4103/idoj.idoj_1248_25","DOIUrl":"https://doi.org/10.4103/idoj.idoj_1248_25","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Akshay Meena, Ravi K Negi, Bheemanathi H Srinivas, Sheetanshu Kumar
{"title":"Topical Tofacitinib in the Treatment of Lichenoid Pseudovesicular Papular Eruptions of the Nose.","authors":"Akshay Meena, Ravi K Negi, Bheemanathi H Srinivas, Sheetanshu Kumar","doi":"10.4103/idoj.idoj_422_26","DOIUrl":"https://doi.org/10.4103/idoj.idoj_422_26","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Senkadhir Vendhan, Rajyalakshmi Konathan, C M Ravi, Rajesh K Godugula
{"title":"Palmoplantar Hyperpigmentation Following Nintedanib Therapy: An Unusual Adverse Effect.","authors":"Senkadhir Vendhan, Rajyalakshmi Konathan, C M Ravi, Rajesh K Godugula","doi":"10.4103/idoj.idoj_1371_25","DOIUrl":"https://doi.org/10.4103/idoj.idoj_1371_25","url":null,"abstract":"","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Siddharth Bhatt, Shital Poojary, Bushra I Khan, Monisha Madhumita, Somesh Gupta, Senkadhir Vendhan
{"title":"Artificial Intelligence in Indian Dermatology: An IADVL Academy Position Statement and Policy Framework for Safe, Equitable, and Effective Adoption.","authors":"Siddharth Bhatt, Shital Poojary, Bushra I Khan, Monisha Madhumita, Somesh Gupta, Senkadhir Vendhan","doi":"10.4103/idoj.idoj_1250_25","DOIUrl":"https://doi.org/10.4103/idoj.idoj_1250_25","url":null,"abstract":"<p><strong>Abstract: </strong>Artificial intelligence (AI) systems, particularly deep learning models, are increasingly used in dermatology for image analysis, triage, remote monitoring, and decision support. For real-world adoption in the Indian dermatology ecosystem, robust validation, transparency, and governance are essential to protect patient safety and equity. This position statement synthesizes guidance from international dermatology societies and major regulatory approaches, and proposes India-adapted recommendations across clinical use, dataset curation, validation standards, ethics, privacy, liability, and policy. We performed a narrative synthesis of position statements from the American Academy of Dermatology (AAD), European Academy of Dermatology and Venereology (EADV), British Association of Dermatologists (BAD), and Australasian College of Dermatologists (ACD); regulatory frameworks, including the European Union Medical Device Regulation (EU MDR), the United States Food and Drug Administration (US FDA) Software as a Medical Device (SaMD) approach, National Institute for Health and Care Excellence (NICE) evidence standards, and Australia's Therapeutic Goods Administration (TGA). Indian frameworks, including the Central Drugs Standard Control Organisation (CDSCO) Medical Device Rules, Bureau of Indian Standards/International Organization for Standardization (BIS/ISO) standards, the Digital Personal Data Protection (DPDP) Act, and Indian Council of Medical Research (ICMR) artificial intelligence ethics guidance were included. Seven domains were analyzed: governance, evidence generation, data bias, clinical safety, privacy, liability, and education. Principles emphasize clinician-in-the-loop use, prospective multicentric validation in representative Indian settings, skin-of-color inclusivity, transparent labeling and explainability, post-market surveillance, and clearer accountability. While clinical utility and health-economic evidence remain limited, validated and inclusive AI tools can responsibly expand access to quality dermatologic care in India, particularly in underserved areas.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Knowledge, Attitude, and Practice of Use of Rituximab in Pemphigus among Indian Dermatologists: A Cross-Sectional Questionnaire-Based Survey.","authors":"Dipankar De, Narayanan Baskaran, Rahul Mahajan, Abir Saraswat, Deepika Pandhi, Geeti Khullar, Kolalapudi Seetharam Anjaneyulu, Manas Chatterjee, Manjunath Shenoy, Murlidhar Rajagopalan, Nayeem Sadath Haneef, Nilay Kanti Das, Raghavendra Rao, Sheetanshu Kumar, Shekhar Neema, Shyamanta Barua, Sujay Khandpur, Vinay Keshavamurthy, Vishal Gupta, Sanjeev Handa","doi":"10.4103/idoj.idoj_631_25","DOIUrl":"https://doi.org/10.4103/idoj.idoj_631_25","url":null,"abstract":"<p><strong>Background: </strong>Rituximab has changed the paradigm for management of pemphigus vulgaris (PV). Despite its widespread use, variability exists in its use, particularly related to dosing protocols, prophylaxis, and use in special populations. This study aimed to assess dermatologists' knowledge, attitude, and practices regarding rituximab in India.</p><p><strong>Materials and methods: </strong>A cross-sectional questionnaire-based survey was conducted among Indian dermatologists with at least six months of clinical experience post-residency between March and June 2024. An 85-question survey was used to gather information on knowledge, attitudes, and practices related to rituximab. Descriptive statistics were employed to analyze the data and identify practice variations.</p><p><strong>Results: </strong>Fifty-five dermatologists with a mean practice experience of 13 years participated. Most (78.2%) preferred rituximab as first-line adjuvant for PV, citing higher remission rates and fewer long-term adverse effects. Knowledge of rituximab's mechanism of action was excellent. However, significant practice variability was observed. The standard dose rheumatoid arthritis protocol for moderate-to-severe disease was preferred by 69.1%, whereas only 14.5% strongly supported low-dose regimens. Screening for latent tuberculosis was commonly performed (80%). Prophylaxis for Pneumocystis jirovecii pneumonia and vaccination practices were inconsistent, with only 12.7% always prescribing prophylaxis. Additionally, 61.8% used rituximab retreatment on clinical relapse, with less emphasis on immunological markers for monitoring.</p><p><strong>Limitations: </strong>The responses may not be representative of all dermatologists, especially those with less experience with rituximab.</p><p><strong>Conclusion: </strong>While dermatologists demonstrated strong knowledge of rituximab, significant variability in dosing, prophylaxis, and retreatment practices exists. Standardized guidelines and educational initiatives may be needed to ensure consistent use of rituximab and improve patient outcomes.</p>","PeriodicalId":13335,"journal":{"name":"Indian Dermatology Online Journal","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}